Head-To-Head Survey: Biotricity (OTCMKTS:BTCY) vs. 111 (NASDAQ:YI)

111 (NASDAQ:YI) and Biotricity (OTCMKTS:BTCY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Risk & Volatility

111 has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Insider and Institutional Ownership

21.3% of 111 shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 43.9% of 111 shares are owned by insiders. Comparatively, 10.1% of Biotricity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares 111 and Biotricity”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
111	$1.97 billion	0.02	-$1.42 million	($0.84)	-4.39
Biotricity	$13.79 million	0.79	-$8.42 million	($0.17)	-2.29

111 has higher revenue and earnings than Biotricity. 111 is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for 111 and Biotricity, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
111	1	0	0	0	1.00
Biotricity	0	0	0	0	0.00

Profitability

This table compares 111 and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
111	-0.52%	N/A	-2.70%
Biotricity	-30.02%	N/A	-75.50%

Summary

111 beats Biotricity on 7 of the 11 factors compared between the two stocks.

About 111

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.